Salivary evaluation in radioactive I131 treated patients with thyroid carcinoma

Acta Odontol Scand. 2018 Mar;76(2):148-152. doi: 10.1080/00016357.2017.1399214. Epub 2017 Nov 10.

Abstract

Background and objective: radioiodine treatment (I131) used to treat thyroid carcinomas produces side effects (sialadenitis, xerostomia, dysphagia and caries susceptibility) reflecting in a poor patient quality of life. This study aimed to evaluate the effect of I131 on salivary function and possible oral impairment.

Material and methods: Thirty-seven patients undergoing I131 were submitted to oral examination, answer questions regarding xerostomia/hyposalivation and collect saliva at three moments (M1: 30-45 days before I131, M2: 1-2 days after I131 and M3: 7-10 days after treatment). Saliva was assayed for flow rate and calcium/phosphate concentrations.

Results and conclusions: significant difference in calcium/phosphate concentration was shown between M1 and M2, with evident decrease at M2. Flow rate reduced right after treatment with 41% of patients returning to previous rate at M3 (no statistical difference). A higher number of patients related xerostomia and difficulty in swallowing food at M2. The results showed that xerostomia/hyposalivation, dysphagia and calcium/phosphate concentration decrease may be considered early radioiodine side effects.

Keywords: Thyroid cancer; iodine radioisotopes; saliva; salivary glands; xerostomia.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Papillary / radiotherapy*
  • Deglutition Disorders / physiopathology
  • Female
  • Humans
  • Iodine Radioisotopes / adverse effects*
  • Male
  • Middle Aged
  • Quality of Life
  • Saliva / radiation effects*
  • Salivary Glands / drug effects
  • Salivary Glands / radiation effects*
  • Sialadenitis / etiology
  • Thyroid Neoplasms / radiotherapy*
  • Xerostomia / chemically induced
  • Xerostomia / etiology

Substances

  • Iodine Radioisotopes